Eldecalcitol is an investigational drug.
There have been 6 clinical trials for Eldecalcitol.
The most recent clinical trial was a Phase 1 trial, which was initiated on June 1st 2023.
The most common disease conditions in clinical trials are Osteoporosis, Osteoporosis, Postmenopausal, and Bone Diseases, Metabolic. The leading clinical trial sponsors are Shinshu University, Chugai Pharma China Co., Ltd., and Wenzhou Haihe Pharmaceutical Co., Ltd.
There are four US patents protecting this investigational drug and one hundred and fifty-three international patents.